Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Multicenter Prospective, Parallel-controlled Phase III Clinical Study on Comparing Efficacy of Tamoxifen Versus Toremifene in CYP2D6 Intermediate/Poor Metabolizers of Premenopausal Patients With ER-positive Early Breast Cancer

NCT03351062 is registered in ClinicalTrials.gov with Chinese Anti-Cancer Association as lead sponsor.

NCT NCT03351062
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03351062 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Multicenter Prospective, Parallel-controlled Phase III Clinical Study on Comparing Efficacy of Tamoxifen Versus Toremifene in CYP2D6 Intermediate/Poor Metabolizers of Premenopausal Patients With ER-positive Early Breast Cancer
Lead sponsor
Chinese Anti-Cancer Association
Phase
Phase 3
Overall status
Unknown status
Start date
November 30, 2017
Completion date
December 31, 2025
Enrollment
844 (estimated)
Sites
21

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer female